NCT05301322 Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age Status COMPLETED Phase PHASE3
NCT05298033 Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo Status COMPLETED Phase PHASE2
NCT05297890 A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05295290 A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. Status ACTIVE_NOT_RECRUITING Phase PHASE4
NCT05288127 Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature Status RECRUITING Phase PHASE2
NCT05287126 A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis Status RECRUITING Phase PHASE2
NCT05286528 Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database Status COMPLETED Phase N/A
NCT05286281 A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803 Status COMPLETED Phase PHASE1
NCT05269069 Impact of Rheumatoid Arthritis on Body Composition, Bone Marrow Adiposity and Bone Mineral Density: a Case-control Study Status TERMINATED Phase N/A
NCT05266105 A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05264493 Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector Status COMPLETED Phase PHASE1
NCT05263921 Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants Status COMPLETED Phase PHASE1
NCT05263908 A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19 Status COMPLETED Phase N/A
NCT05263895 Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation Status COMPLETED Phase PHASE1
NCT05263609 Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib Status WITHDRAWN Phase PHASE2
NCT05262517 Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for Acute Treatment of Temporomandibular Disorders Status TERMINATED Phase PHASE3
NCT05262400 A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05261490 Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer Status TERMINATED Phase PHASE1/PHASE2
NCT05261139 EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease Status RECRUITING Phase PHASE3